Pharmacogenomics for Pain Management: Why Opioids Work Differently for Everyone

Two patients walk into a clinic with identical post-surgical pain scores. They receive the same prescription: codeine 30 mg every four to six hours as needed. Three days later, one patient calls to say the medication is doing nothing — she might as well be swallowing sugar tablets. The other is in the emergency department, unresponsive, with dangerously suppressed breathing. Same drug, same dose, radically different outcomes. The reason lies not in the surgery, not in willpower, not in pain tolerance — it lies in a single gene.

The CYP2D6 gene encodes a liver enzyme responsible for converting codeine into morphine, the compound that actually suppresses pain. Genetic variants in CYP2D6 create a spectrum of enzyme activity ranging from none at all to several times the normal rate. Patients at either extreme of this spectrum face serious risks from drugs that billions of people are prescribed every year without any genetic consideration whatsoever. Pharmacogenomics — the study of how genes influence drug response — offers a way to identify those patients before harm occurs, and to select safer, more effective alternatives. As our introduction to pharmacogenomics explains, this field is rapidly maturing from research novelty to clinical standard of care.

The CYP2D6 Spectrum: From Poor to Ultrarapid

Four Phenotypes, Four Very Different Drug Responses

Pharmacogenomicists classify CYP2D6 activity into four broad phenotypes based on which gene variants a patient carries. Poor metabolisers carry two non-functional copies of the gene and produce little or no functional enzyme. Intermediate metabolisers have reduced activity — typically one functional and one reduced-function allele. Normal (or extensive) metabolisers, which represent roughly 70-80% of most European and East Asian populations, have standard enzyme activity. Ultrarapid metabolisers carry gene duplications that produce abnormally high enzyme activity, sometimes converting drugs so rapidly that standard doses fail or become toxic.

For opioids that are prodrugs — drugs that must be metabolised to become active — this spectrum creates starkly different clinical realities. Poor metabolisers prescribed codeine or tramadol experience minimal pain relief because they cannot generate sufficient active metabolite. They may be labelled as drug-seeking or exaggerating their symptoms when in fact they are simply unable to respond to the medication as intended. Meanwhile, ultrarapid metabolisers convert the same prodrug so efficiently that they reach toxic plasma concentrations of morphine or O-desmethyltramadol within hours. The US FDA issued a black-box warning on codeine for ultrarapid metabolisers in 2012 after multiple deaths, including several nursing infants who received morphine through breast milk from ultrarapid metaboliser mothers prescribed post-partum codeine.

Beyond Codeine: The Broader Opioid Picture

Tramadol presents a similar CYP2D6-dependent activation pattern. The drug itself has only weak opioid activity; its primary analgesic effect comes from O-desmethyltramadol (M1), produced by CYP2D6. Poor metabolisers fail to generate sufficient M1 and receive inadequate analgesia from tramadol, while ultrarapid metabolisers are at elevated seizure and respiratory depression risk. Hydrocodone follows the same pathway. Even oxycodone, which has some intrinsic receptor binding activity without metabolic conversion, relies partly on CYP2D6 for the conversion to oxymorphone, a considerably more potent opioid agonist. Patients who are CYP2D6 ultrarapid metabolisers taking extended-release oxycodone formulations may therefore experience unexpectedly intense effects.

Other Genes That Shape Pain Drug Response

CYP3A4 and CYP3A5: The Fentanyl and Methadone Axis

While CYP2D6 dominates the opioid pharmacogenomics conversation, it is far from the only relevant gene. Fentanyl and methadone — two of the most widely used opioids in both acute and chronic pain settings — are primarily metabolised by CYP3A4 and CYP3A5. Variants in these genes affect clearance rates and therefore the duration and intensity of drug action. CYP3A5 expressers (carrying at least one CYP3A5*1 allele) metabolise certain substrates faster than non-expressers. CYP3A5 expression rates differ by ancestry: roughly 10-40% of Europeans express CYP3A5 compared to 50-70% of people of African ancestry, introducing another layer of pharmacokinetic variability.

Methadone pharmacogenomics is particularly complex. Methadone exists as two enantiomers with different metabolic pathways and receptor affinities. R-methadone is the more potent opioid agonist and is metabolised primarily by CYP3A4, while S-methadone, which contributes to QT interval prolongation risk, is metabolised by both CYP3A4 and CYP2D6. This multi-enzyme involvement means that genetic variants in several pathways simultaneously influence methadone's safety profile, making pharmacogenomic testing particularly valuable for patients initiating methadone for chronic pain or opioid use disorder.

CYP2C9 and NSAIDs

Non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line agents for many pain conditions, yet they carry well-recognised risks of gastrointestinal bleeding and renal impairment that are partly genetically mediated. CYP2C9 metabolises ibuprofen, diclofenac, celecoxib, and several other NSAIDs. Poor metabolisers with CYP2C9*2 or CYP2C9*3 variants accumulate higher plasma drug concentrations and experience prolonged drug exposure, increasing both efficacy and toxicity. For celecoxib, the FDA-approved label already includes pharmacogenomic dosing guidance for CYP2C9 poor metabolisers, recommending a 50% dose reduction. This represents one of the clearest examples of pharmacogenomics being formally embedded in prescribing guidance for a commonly used pain drug.

Antidepressants for Neuropathic Pain: A CYP2D6 and CYP2C19 Story

Tricyclics, SNRIs, and the Metaboliser Problem

Chronic neuropathic pain — from diabetic peripheral neuropathy, post-herpetic neuralgia, fibromyalgia, or central sensitisation — is frequently treated with antidepressants at sub-psychiatric doses. Amitriptyline, nortriptyline, duloxetine, and venlafaxine are all first or second-line agents for various neuropathic pain conditions. All of them are substantially metabolised by CYP2D6, and several also depend on CYP2C19. The clinical implications mirror those seen with opioids: poor metabolisers accumulate drug, achieving higher plasma concentrations and increased side-effect burden at standard doses; ultrarapid metabolisers may fail to reach therapeutic concentrations and experience no benefit.

For amitriptyline, the Clinical Pharmacogenomics Implementation Consortium (CPIC) guidelines — the gold standard for translating pharmacogenomic evidence into prescribing recommendations — advise avoiding amitriptyline in CYP2D6 ultrarapid and poor metabolisers. Intermediate metabolisers are advised to use a 25% dose reduction. Similar guidance exists for nortriptyline and other tricyclics. For patients with neuropathic pain who have failed multiple antidepressant trials, unrecognised CYP2D6 or CYP2C19 variants may be a significant contributing factor. This is exactly the population for whom pharmacogenomic testing delivers the most immediate clinical value — patients stuck in an ineffective prescribing loop. The broader implications for precision medicine in mental health extend these same principles across psychiatric prescribing.

Duloxetine and Venlafaxine in Practice

Duloxetine (Cymbalta) is now one of the most prescribed agents for both diabetic neuropathic pain and fibromyalgia. It is a CYP2D6 substrate but not, crucially, a prodrug — so the relationship between metaboliser status and outcome is somewhat different from codeine. Poor metabolisers achieve higher duloxetine exposures than normal metabolisers and face elevated rates of nausea, insomnia, and hypertension. Venlafaxine is converted to its active metabolite O-desmethylvenlafaxine (desvenlafaxine) by CYP2D6, making it more analogous to the prodrug opioids. Poor metabolisers on venlafaxine have reduced conversion to the active metabolite and may experience reduced efficacy for pain. Pharmacogenomic testing thus helps clinicians choose not only which antidepressant to try, but what starting dose is appropriate given the patient's metabolic profile.

What a Pain Pharmacogenomic Panel Actually Tests

Genes, Variants, and the Clinical Report

A comprehensive pain pharmacogenomic panel typically analyses six to ten genes. The core set includes CYP2D6 (opioid prodrugs, tricyclics, some antidepressants), CYP2C9 (NSAIDs, some opioids), CYP2C19 (certain antidepressants used for pain, proton pump inhibitors often co-prescribed), CYP3A4 and CYP3A5 (fentanyl, methadone, oxycodone), and OPRM1 (opioid receptor sensitivity). Some panels additionally include COMT (catechol-O-methyltransferase), variants in which are associated with differential pain perception and morphine dose requirements; ABCB1, encoding P-glycoprotein which influences drug transport into the central nervous system; and UGT2B7, which glucuronidates morphine into its active and inactive metabolites.

The clinical report translates raw genotype findings into actionable phenotype classifications and drug-specific guidance. Rather than presenting raw variant data, modern pharmacogenomic reports are structured to give prescribers clear, actionable information: "For this patient, codeine and tramadol are not recommended (CYP2D6 ultrarapid metaboliser). Consider morphine with reduced starting dose or buprenorphine, which is not CYP2D6 dependent." This kind of prescriber-ready output is critical for clinical adoption — a result that requires specialist genetic interpretation to act upon will not be used at the point of care. As we explore in our article on what precision medicine means in practice, the translation of genomic data into clinical decision support is where much of the real implementation challenge lies.

Opioid-Sparing Alternatives and the Genetic Context

One of the most clinically important applications of pain pharmacogenomics is identifying patients for whom opioid alternatives are preferable not just because of addiction risk but because of metabolic unsuitability. Buprenorphine and tapentadol are two agents that have become particularly attractive in this context. Buprenorphine is not a CYP2D6 substrate — it is metabolised primarily by CYP3A4 and to a lesser extent CYP2C8 — making it a viable option for patients whose CYP2D6 status makes codeine or tramadol inappropriate. Tapentadol has dual mechanisms (mu-opioid agonism plus noradrenaline reuptake inhibition) and while it does have some CYP2D6 metabolism, it is less dependent on this pathway than the classic prodrug opioids. Pharmacogenomic results thus expand the precision of opioid selection rather than simply excluding patients from opioid therapy entirely.

The Evidence Base: What Clinical Studies Show

From Association Studies to Randomised Trials

The evidence supporting pharmacogenomic-guided pain management has matured considerably over the past decade, moving from pharmacokinetic association studies to prospective clinical trials. A landmark study published in the European Journal of Pain demonstrated that pharmacogenomic-guided opioid prescribing significantly reduced time to adequate pain control and reduced opioid dose requirements in patients with chronic musculoskeletal pain compared to standard care. The PRIMER trial, examining pharmacogenomic-guided prescribing in primary care pain patients, found meaningful reductions in adverse drug events over six months in the guided group. Multiple systematic reviews and meta-analyses have now confirmed associations between CYP2D6 and CYP2C9 phenotype and clinically meaningful outcomes including analgesic efficacy, adverse events, and opioid dose requirements.

The evidence is most robust for CYP2D6 and CYP2C9 — the two genes with the clearest pharmacokinetic-to-pharmacodynamic translation and the most replicated clinical data. Evidence for OPRM1 and COMT is more nuanced: effect sizes are smaller and more context-dependent, though these genes are increasingly viewed as clinically relevant for dose optimisation rather than drug selection. The CPIC consortium publishes living guidelines that are updated as new evidence emerges; their pain-related guidelines currently cover codeine, tramadol, NSAIDs, and tricyclic antidepressants with grades of clinical actionability ranging from strong to moderate. These guidelines represent the clearest translation of pharmacogenomic science into clinical practice standards. For a broader view of how genomic science is reshaping all of medicine, our article on AI and machine learning in genomics explores how computational tools are accelerating our understanding of gene-drug interactions at scale.

Health Economics and Cost-Effectiveness

Pharmacogenomic testing costs have fallen dramatically. Panels that once cost several thousand dollars are now available for $200-400, with some insurance-reimbursed versions available at no out-of-pocket cost to patients meeting clinical criteria. Multiple health economic analyses have found that pharmacogenomic-guided prescribing is cost-effective or even cost-saving when avoiding a single serious adverse drug event — hospitalisation for respiratory depression, for example, typically costs many multiples of the test price. In chronic pain patients on long-term opioid therapy, the cumulative benefit of optimised prescribing over months to years strengthens the economic case considerably. As test prices continue to fall and clinical uptake grows, pharmacogenomic testing for pain is expected to follow the trajectory of oncology pharmacogenomics, where it has become routine for many tumour types — as described in our article on precision oncology and tumour profiling.

Barriers to Implementation and How They Are Being Overcome

Prescriber Education and Clinical Decision Support

Despite compelling evidence and falling costs, pharmacogenomic testing for pain remains underutilised in routine clinical practice. Surveys of primary care physicians and pain specialists consistently identify the same barriers: unfamiliarity with gene-drug interaction evidence, uncertainty about how to interpret results, lack of time to integrate testing into the clinical workflow, and absence of pharmacogenomic consultation services at most hospitals. These are real obstacles, but they are addressable. Clinical pharmacists trained in pharmacogenomics have emerged as key implementation partners in settings where testing programmes have succeeded. Electronic health record (EHR) integration of pharmacogenomic alerts — passive clinical decision support that flags relevant interactions at the point of prescribing — has shown particular promise for closing the gap between genotype result and prescribing action.

Several large health systems in the United States, including Vanderbilt University Medical Center and the Mayo Clinic, have implemented preemptive pharmacogenomic testing programmes in which patients are genotyped once and results are stored in their EHR for lifetime use. This preemptive model eliminates the logistical barrier of ordering a test in the moment it is needed, ensures results are available before the first prescription is written, and builds a genomic infrastructure that benefits patients across all future prescribing encounters. Implementing such programmes requires upfront investment in laboratory infrastructure, EHR integration, and clinician education, but the long-term value proposition is compelling. As precision medicine becomes standard rather than specialty care, these models are being adapted for broader health system adoption globally.

Polypharmacy and Drug-Drug-Gene Interactions

A further complexity in pain pharmacogenomics is the prevalence of polypharmacy. Patients with chronic pain are often prescribed multiple drugs simultaneously — an opioid, an antidepressant, a gabapentinoid, a muscle relaxant, and various co-morbidity medications. Many drugs are not only CYP substrates but also CYP inhibitors or inducers. Fluoxetine and paroxetine, commonly prescribed antidepressants, are potent CYP2D6 inhibitors that can functionally convert a normal metaboliser into a phenocopy of a poor metaboliser. This drug-drug interaction can render a patient's CYP2D6 genotype irrelevant to their actual drug response until the inhibitor is withdrawn. Sophisticated pharmacogenomic clinical decision support tools increasingly account for these drug-drug-gene interactions, generating phenoconversion alerts that adjust predicted metaboliser status based on concurrent medications. This intersection of genomics and polypharmacy management represents one of the most complex and clinically important frontiers in pain pharmacology.

The Future: Integrating Pain Genomics with the Broader Precision Medicine Vision

From Single Genes to Polygenic Pain Profiles

Current pharmacogenomic panels focus on pharmacokinetic genes — those that determine how drugs are processed. The next frontier is pharmacodynamic genomics: genes that influence pain perception, central sensitisation, inflammatory response, and the neurobiological factors underlying why some people develop chronic pain while others do not. COMT variants affecting catecholamine breakdown, TRPV1 variants affecting nociceptor sensitivity, and SCN9A variants in sodium channel function are among the targets under active investigation. Polygenic risk scores for chronic pain susceptibility are in early development, with the goal of identifying patients at high risk for chronic pain transition following acute injury or surgery — enabling pre-emptive multimodal analgesia strategies rather than reactive opioid escalation after the fact.

The integration of pharmacogenomics with other precision medicine data streams — gut microbiome composition, which influences drug metabolism through microbial enzymatic activity; epigenetic modifications that alter gene expression without changing the underlying DNA sequence; and real-time physiological monitoring through wearables — will eventually create a far richer picture of individual pain biology than any single genetic panel can provide. The convergence of these data types with AI-powered clinical decision support systems is already underway in research settings. The same principles that are transforming cancer care through precision oncology are being systematically applied to pain management, with the goal of matching every patient to the drug, dose, and delivery method that their unique biology indicates is most likely to succeed. As this vision becomes reality, the one-size-fits-all approach to pain prescribing will seem as outdated as prescribing the same chemotherapy to every cancer patient regardless of tumour genetics.

For patients currently living with inadequately controlled pain, or who have experienced frightening adverse events on standard pain medications, pharmacogenomic testing represents an actionable option available today — not a distant research promise. A conversation with a pain specialist or clinical pharmacist about whether testing is appropriate is a reasonable first step for anyone who has found that their pain medications work differently than expected, or who has experienced side effects that seemed disproportionate to the dose prescribed.